34 related articles for article (PubMed ID: 26163638)
1. Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma.
Li F; Aljahdali IAM; Zhang R; Nastiuk KL; Krolewski JJ; Ling X
J Exp Clin Cancer Res; 2021 Aug; 40(1):254. PubMed ID: 34384473
[TBL] [Abstract][Full Text] [Related]
2. A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma.
Kanesvaran R; Watt K; Turnbull JD; Armstrong AJ; Wolkowiez MC; George DJ
Clin Genitourin Cancer; 2015 Aug; 13(4):319-327. PubMed ID: 26174223
[TBL] [Abstract][Full Text] [Related]
3. Review of Prognostic Expression Markers for Clear Cell Renal Cell Carcinoma.
Petitprez F; Ayadi M; de Reyniès A; Fridman WH; Sautès-Fridman C; Job S
Front Oncol; 2021; 11():643065. PubMed ID: 33996558
[No Abstract] [Full Text] [Related]
4. Long non‑coding RNA PCAT6 promotes the development of osteosarcoma by increasing MDM2 expression.
Guan X; Xu Y; Zheng J
Oncol Rep; 2020 Dec; 44(6):2465-2474. PubMed ID: 33125146
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and clinicopathological value of p53 expression in renal cell carcinoma: a meta-analysis.
Wang Z; Peng S; Jiang N; Wang A; Liu S; Xie H; Guo L; Cai Q; Niu Y
Oncotarget; 2017 Nov; 8(60):102361-102370. PubMed ID: 29254251
[TBL] [Abstract][Full Text] [Related]
6. Copy number variation of E3 ubiquitin ligase genes in peripheral blood leukocyte and colorectal cancer.
Bi H; Tian T; Zhu L; Zhou H; Hu H; Liu Y; Li X; Hu F; Zhao Y; Wang G
Sci Rep; 2016 Jul; 6():29869. PubMed ID: 27417709
[TBL] [Abstract][Full Text] [Related]
7. Long-term survival of patients with unilateral sporadic multifocal renal cell carcinoma according to histologic subtype compared with patients with solitary tumors after radical nephrectomy.
Dimarco DS; Lohse CM; Zincke H; Cheville JC; Blute ML
Urology; 2004 Sep; 64(3):462-7. PubMed ID: 15351571
[TBL] [Abstract][Full Text] [Related]
8. p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?
Noon AP; Vlatković N; Polański R; Maguire M; Shawki H; Parsons K; Boyd MT
Cancer; 2010 Feb; 116(4):780-90. PubMed ID: 20052733
[TBL] [Abstract][Full Text] [Related]
9. Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy.
Noon AP; Polański R; El-Fert AY; Kalirai H; Shawki H; Campbell F; Dodson A; Eccles RM; Lloyd BH; Sibson DR; Coupland SE; Lake SL; Parsons K; Vlatković N; Boyd MT
BJU Int; 2012 Apr; 109(8):1250-7. PubMed ID: 21756282
[TBL] [Abstract][Full Text] [Related]
10. p53-expression in patients with renal cell carcinoma correlates with a higher probability of disease progression and increased cancer-specific mortality after surgery but does not enhance the predictive accuracy of robust outcome models.
Morshaeuser L; May M; Burger M; Otto W; Hutterer GC; Pichler M; Klatte T; Wild P; Buser L; Brookman-May S
Urol Oncol; 2018 Mar; 36(3):94.e15-94.e21. PubMed ID: 29221641
[TBL] [Abstract][Full Text] [Related]
11. Vimentin over-expression and carbonic anhydrase IX under-expression are independent predictors of recurrence, specific and overall survival in non-metastatic clear-cell renal carcinoma: a validation study.
Ingels A; Hew M; Algaba F; de Boer OJ; van Moorselaar RJ; Horenblas S; Zondervan P; de la Rosette JJ; Pilar Laguna Pes M
World J Urol; 2017 Jan; 35(1):81-87. PubMed ID: 27207480
[TBL] [Abstract][Full Text] [Related]
12. Is there a role for partial nephrectomy in patients with metastatic renal cell carcinoma?
Hellenthal NJ; Mansour AM; Hayn MH; Schwaab T
Urol Oncol; 2013 Jan; 31(1):36-41. PubMed ID: 21396834
[TBL] [Abstract][Full Text] [Related]
13. Prognostic features of pathologic stage T1 renal cell carcinoma after radical nephrectomy.
Lau WK; Cheville JC; Blute ML; Weaver AL; Zincke H
Urology; 2002 Apr; 59(4):532-7. PubMed ID: 11927308
[TBL] [Abstract][Full Text] [Related]
14. P53 and MDM2 Over-expression and Five-year Survival of Kidney Cancer Patients Undergoing Radical Nephrectomy--Iranian Experience.
Abolhasani M; Salarinejad S; Asgari M
Asian Pac J Cancer Prev; 2015; 16(12):5043-7. PubMed ID: 26163638
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
